NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for

  NPS Pharmaceuticals to Host Conference Call to Discuss FDA Approval of
  Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult
  Short Bowel Syndrome

Business Wire

BEDMINSTER, N.J. -- January 2, 2013

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to
discuss its commercialization plan for Gattex, including the cost of therapy,
today at 5:00 p.m. Eastern Time. To participate in the conference call, dial
(800) 706-7748 and use pass code 18085144. International callers may dial
(617) 614-3473, using the same pass code. In addition, a live audio of the
conference call will be available over the Internet. Interested parties can
access the event through the investors’ calendar of events page on the NPS
website at http://www.npsp.com/calendar.

For those unable to participate in the live call, a replay will be available
at (888) 286-8010, with pass code 79197503, until midnight Eastern Time,
January 16, 2013. International callers may access the replay by dialing (617)
801-6888, using the same pass code. The webcast will also be available through
the NPS website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
The company’s lead product, Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin])
for Injection, for subcutaneous use is FDA-approved for the treatment of adult
patients with short bowel syndrome (SBS) who are dependent on parenteral
support. NPS is also developing Natpara^® (rhPTH[1-84]) for the treatment of
adult hypoparathyroidism and expects to submit its Biologic License
Application (BLA) to the FDA in mid-2013. NPS's earlier stage pipeline
includes two calcilytic compounds, NPSP790 and NPSP795, with potential
application in rare disorders involving increased calcium receptor activity,
such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS
complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen,
GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.

Contact:

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335